An oral formulation of azacitidine has been shown to improve overall and relapse free survival in patients with AML in their first remission after intensive chemotherapy. Associate Professor Andrew Wei, head of leukaemia research at The Alfred, told the ASH 2019 meeting in Orlando that the drug known as CC-486 was the first maintenance therapy ...
Oral azacitidine maintenance therapy improves OS in AML
By Mardi Chapman
16 Jan 2020